NeuroMab™ Anti-CD33 BBB Shuttle Antibody(NRZP-1022-ZP3565)

Figure 1 shows the results of competition binding experiments, in which 125I-labeled My9-6 antibody (3×10-9 M) was bound to My9 or My9-6 antibody.

Figure 17 shows My9-6 KD values calculated by direct binding assays on HL-60 membranes and HL-60 whole cells and competition binding assays on HL-60 membranes. N≥3 except * where N=2.

Figure 18 shows the binding curve of huMy9-6 V1.0: direct binding on HL-60 membrane.

Figure 19 shows a comparison of the binding of My9-6-DM1 and My9-6 antibody on HL-60 cells.

Figure 20 shows the in vitro cytotoxicity of My9-6-DM1 on human tumor cells expressing CD33.

Figure 21 shows the results of efficacy experiments of My9-6-DM1 in SCID mice bearing HL-60 xenografts. The effect of My9-6-DM1 (A) and unmodified My9-6 antibody (C) on HL-60 tumor growth was assessed. Mouse body weight was monitored as an indicator of toxicity (B, D).

Figure 22 shows a comparison of the efficacy of My9-6-DM1 and the free drug maytansine in SCID mice bearing HL-60 xenografts (A). Mouse body weight was monitored as an indicator of toxicity (B). Recurrent tumors in two treated mice were treated with a second course of My9-6-DM1.

Figure 23A shows a comparison of the antitumor efficacy of My9-6-DM1 versus standard chemotherapy in SCID mice bearing large HL-60 xenografts.

Figure 24 shows the antitumor efficacy of My9-6-DM1 compared to Gentuzumab ozogamicin and standard chemotherapy in the HL-60 survival model. HL-60 cells were injected intravenously into SCID mice. The indicated treatments started 11 days after cell injection. Except Gentuzumab ozogamicin (Q4D×3), the treatment was iv ×5 per day.

Figure 24 shows the antitumor efficacy of My9-6-DM1 compared to Gentuzumab ozogamicin and standard chemotherapy in the HL-60 survival model. HL-60 cells were injected intravenously into SCID mice. The indicated treatments started 11 days after cell injection. Except Gentuzumab ozogamicin (Q4D×3), the treatment was iv ×5 per day.

Figure 23 shows monitoring of mouse body weight as an indicator of toxicity. Recurrent tumors in two treated mice were treated with a second course of My9-6-DM1.

Figure 22 Monitor mouse body weight as an indicator of toxicity. Recurrent tumors in two treated mice were treated with a second course of My9-6-DM1.

Figure 18 shows the binding curve of huMy9-6 V1.0. Binds directly to HL-60 whole cells.

Figure 18 shows the binding curve of huMy9-6 V1.0. Competitive binding on HL-60 membranes.